SB-007, we’ve been expecting you
Introducing Splice Bio, a genetic medicines company with some exciting developments for Stargardt’s patients.
Search
Search results
VG801 gene therapy shows early promise for Stargardt disease in phase 1/2 clinical trial
VeonGen has reported encouraging early results from a clinical trial of VG801, an investigational gene therapy for Startgardt disease, a genetic retinal condition that currently has no approved treatments.
Opus Genetics completes enrolment in phase 3 trial of OPGx-LCA5
Opus Genetics has completed enrolment in its registrational phase 3 clinical trial of OPGx-LCA5, an investigational gene therapy for LCA5-related Leber Congenital Amaurosis (LCA).
Children and young people
Different inherited sight loss conditions present noticeable symptoms at different times.
Meet a Researcher: Jing Yu
Jing Yu is a Research Assistant at the Nuffield Department of Clinical Neurosciences at the John Radcliffe Hospital in Oxford.
e-Newsletter May 2024
Our monthly e-Newsletter featuring the latest updates from Retina UK.
e-Newsletter June 2023
Our monthly e-Newsletter featuring the latest updates from Retina UK. Subscribe now to receive these updates directly to your email.
E-Newsletter September 2026
Our monthly e-Newsletter featuring the latest updates from Retina UK.
A genetic diagnosis for RP can give rise to unexpected surprises
James Birtley is a Retina UK supporter and volunteer who is living with retinitis pigmentosa. He is also a scientist with a particular interest in the structure of proteins, the complex molecules that form the building blocks of our bodies.
Experimental therapy by Retina UK-funded researchers leads to ‘life changing improvements’
Researchers who received funding from Retina UK have carried out experimental gene therapy that is reported to have led to ‘life changing improvements’ to sight for four children with inherited sight loss.